dipyridamole has been researched along with Diabetic Glomerulosclerosis in 23 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 7.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "When treated with dipyridamole for 9." | 5.28 | Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria. ( Aizawa, T; Asawa, T; Hashizume, K; Hiramatsu, K; Katakura, M; Komatsu, M; Okada, N; Shigematsu, S; Shinoda, T; Suzuki, S, 1990) |
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 3.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "To assess coronary blood flow velocity in young patients with type 1 DM using transoesophageal Doppler echocardiography with dipyridamole and to analyse the possible relationship between the impairment of coronary flow and retinopathy as well as microalbuminuria." | 3.74 | Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus. ( Biegalski, W; Dankowski, R; Kandziora, M; Michalski, M; Naskret, D; Poprawski, K; Wierzchowiecki, M, 2008) |
| " SMI was assessed by either exercise or dipyridamole single-photon emission-computed tomography myocardial perfusion imaging with thallium-201." | 3.73 | Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. ( Attali, JR; Brulport-Cerisier, V; Cosson, E; Estour, B; Halimi, S; Lormeau, B; Maréchaud, R; Pariès, J; Sachs, RN; Torremocha, F; Valensi, P; Vanzetto, G, 2005) |
| "Seventy-six patients with type-2 diabetic nephropathy, who had normal renal function tests were randomized into the 4 groups; each group (n = 19) received one of the following treatments: aspirin (1000 mg), dipyridamole (750 mg), their combination or placebo daily for 2 months." | 2.70 | A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. ( Khajehdehi, P; Mostafavi, H; Roozbeh, J, 2002) |
| "Treatment with aspirin-dipyridamole was without effect." | 2.66 | Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy. ( Barker, MJ; Davies, JA; Hooper, AH; Spencer, AA; Stainton, C; Tindall, H, 1986) |
| "Dipyridamole is a platelet inhibitor indicated for the secondary prevention of transient ischemic attack." | 2.50 | Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? ( Balakumar, P; Dhanaraj, SA; Nyo, YH; Oh, AN; Raaginey, D; Renushia, R; Varatharajan, R, 2014) |
| "When treated with dipyridamole for 9." | 1.28 | Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria. ( Aizawa, T; Asawa, T; Hashizume, K; Hiramatsu, K; Katakura, M; Komatsu, M; Okada, N; Shigematsu, S; Shinoda, T; Suzuki, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (34.78) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balakumar, P | 2 |
| Nyo, YH | 2 |
| Renushia, R | 2 |
| Raaginey, D | 2 |
| Oh, AN | 2 |
| Varatharajan, R | 2 |
| Dhanaraj, SA | 2 |
| Akhtar, SS | 1 |
| Rupeshkumar, M | 1 |
| Sundram, K | 1 |
| Elsherbiny, NM | 1 |
| Al-Gayyar, MM | 1 |
| Abd El Galil, KH | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| Valensi, P | 1 |
| Pariès, J | 1 |
| Brulport-Cerisier, V | 1 |
| Torremocha, F | 1 |
| Sachs, RN | 1 |
| Vanzetto, G | 1 |
| Cosson, E | 1 |
| Lormeau, B | 1 |
| Attali, JR | 1 |
| Maréchaud, R | 1 |
| Estour, B | 1 |
| Halimi, S | 1 |
| Dankowski, R | 1 |
| Wierzchowiecki, M | 1 |
| Naskret, D | 1 |
| Michalski, M | 1 |
| Kandziora, M | 1 |
| Biegalski, W | 1 |
| Poprawski, K | 1 |
| Makino, H | 1 |
| Okada, S | 1 |
| Ota, Z | 1 |
| Wilson, RA | 1 |
| Norman, DJ | 1 |
| Barry, JM | 1 |
| Bennett, WM | 1 |
| Mistry, BM | 1 |
| Bastani, B | 1 |
| Solomon, H | 1 |
| Hoff, J | 2 |
| Aridge, DL | 1 |
| Lindsey, LM | 1 |
| Schmid, S | 1 |
| Chaitman, BR | 2 |
| Garvin, PJ | 2 |
| Castells, I | 1 |
| Salinas, I | 1 |
| Rius, F | 1 |
| Fraile, M | 1 |
| Rubio, L | 1 |
| Pereferrer, D | 1 |
| Romero, R | 1 |
| Sanmartí, A | 1 |
| Fuster, D | 1 |
| Magriñá, J | 1 |
| Ricart, MJ | 1 |
| Pascual, J | 1 |
| Laterza, C | 1 |
| Setoain, FJ | 1 |
| Vidal-Sicart, S | 1 |
| Mateos, JJ | 1 |
| Martín, F | 1 |
| Muxí, A | 1 |
| Khajehdehi, P | 1 |
| Roozbeh, J | 1 |
| Mostafavi, H | 1 |
| Gordge, MP | 1 |
| Rylance, PB | 1 |
| Neild, GH | 1 |
| Aizawa, T | 1 |
| Suzuki, S | 1 |
| Asawa, T | 1 |
| Komatsu, M | 1 |
| Shigematsu, S | 1 |
| Okada, N | 1 |
| Katakura, M | 1 |
| Hiramatsu, K | 1 |
| Shinoda, T | 1 |
| Hashizume, K | 1 |
| Camp, AD | 1 |
| Marsh, J | 1 |
| Byers, SL | 1 |
| Gibb, DM | 1 |
| Dunger, D | 1 |
| Levin, M | 1 |
| Grant, D | 1 |
| Jones, P | 1 |
| Barratt, TM | 1 |
| Hopper, AH | 1 |
| Tindall, H | 2 |
| Davies, JA | 2 |
| Brown, KA | 1 |
| Rimmer, J | 1 |
| Haisch, C | 1 |
| Hara, S | 1 |
| Mimura, N | 1 |
| Nath, KA | 1 |
| Donadio, JV | 1 |
| Ilstrup, DM | 1 |
| Holley, KE | 1 |
| Romero, JC | 1 |
| Hooper, AH | 1 |
| Barker, MJ | 1 |
| Spencer, AA | 1 |
| Stainton, C | 1 |
| George, CR | 1 |
| Slichter, SJ | 1 |
| Quadracci, LJ | 1 |
| Striker, GE | 1 |
| Harker, LA | 1 |
3 reviews available for dipyridamole and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetic Nephropathies; Dipyridamole; Humans; Phosp | 2014 |
Noninvasive cardiac testing in the end-stage renal disease patient.
Topics: Coronary Disease; Diabetic Nephropathies; Dipyridamole; Dobutamine; Echocardiography; Exercise Test; | 1994 |
Platelets, antiplatelet therapy, and diabetic nephropathy.
Topics: Aspirin; Diabetic Nephropathies; Dipyridamole; Humans; Kidney Failure, Chronic; Platelet Aggregation | 1988 |
4 trials available for dipyridamole and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
Topics: Adult; Aged; Aspirin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipyridamole; Drug Administ | 2002 |
Absence of effect of dipyridamole on renal and platelet function in diabetes mellitus.
Topics: Adolescent; Albuminuria; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipyridamole; Double-Bli | 1990 |
Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.
Topics: Adult; Aspirin; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipyridamole; Double-Blind Method | 1989 |
Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy.
Topics: Aspirin; Blood Glucose; Blood Platelets; Cell Survival; Diabetic Nephropathies; Dipyridamole; Double | 1986 |
16 other studies available for dipyridamole and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropat | 2014 |
Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis.
Topics: Adenosine; Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2015 |
Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blotting, Western; Cr | 2003 |
Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study.
Topics: Aging; Algorithms; Chi-Square Distribution; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus; Dia | 2005 |
Association between retinopathy, microalbuminuria and coronary perfusion in young patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Albuminuria; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Diabete | 2008 |
Effect of dipyridamole on proteinuria of diabetic nephropathy.
Topics: Diabetic Nephropathies; Dipyridamole; Humans; Male; Middle Aged; Proteinuria | 1983 |
Prognostic value of dipyridamole thallium-201 screening to minimize perioperative cardiac complications in diabetics undergoing kidney or kidney-pancreas transplantation.
Topics: Adult; Coronary Angiography; Coronary Disease; Diabetic Nephropathies; Dipyridamole; Female; Heart; | 1998 |
Inducible myocardial ischaemia in asymptomatic Type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephr | 2000 |
Noninvasive assessment of cardiac risk in type I diabetic patients being evaluated for combined pancreas-kidney transplantation using dipyridamole-MIBI perfusion tomographic scintigraphy.
Topics: Adult; Contraindications; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipyridamole; Exercise | 2000 |
Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
Topics: Aspirin; Blood Pressure; Creatinine; Diabetic Nephropathies; Dipyridamole; Docosahexaenoic Acids; Dr | 1992 |
Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria.
Topics: Adult; Aged; Albuminuria; beta 2-Microglobulin; Blood Pressure; Diabetes Complications; Diabetes Mel | 1990 |
Prognostic value of intravenous dipyridamole thallium imaging in patients with diabetes mellitus considered for renal transplantation.
Topics: Adult; Coronary Disease; Diabetic Nephropathies; Dipyridamole; Female; Humans; Kidney Transplantatio | 1990 |
Noninvasive cardiac risk stratification of diabetic and nondiabetic uremic renal allograft candidates using dipyridamole-thallium-201 imaging and radionuclide ventriculography.
Topics: Adult; Diabetic Nephropathies; Dipyridamole; Female; Follow-Up Studies; Humans; Kidney Transplantati | 1989 |
[Glomerular diseases secondary to diabetes mellitus].
Topics: Adult; Diabetic Nephropathies; Dipyridamole; Humans; Hypertension, Renal; Indomethacin; Kidney Trans | 1988 |
Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study.
Topics: Adult; Aspirin; Blood Platelets; Cell Survival; Creatinine; Diabetic Nephropathies; Dipyridamole; Dr | 1988 |
A kinetic evaluation of hemostasis in renal disease.
Topics: Aspirin; Blood Coagulation; Complement System Proteins; Diabetic Nephropathies; Dipyridamole; Fibrin | 1974 |